186 related articles for article (PubMed ID: 3312023)
41. Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients.
Cies JJ; Varlotta L
Pediatr Pulmonol; 2013 Dec; 48(12):1190-4. PubMed ID: 23281228
[TBL] [Abstract][Full Text] [Related]
42. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
43. Paranasal sinus pathogens in children with cystic fibrosis: do they relate to lower respiratory tract pathogens and is eradication successful?
Wilson P; Lambert C; Carr SB; Pao C
J Cyst Fibros; 2014 Jul; 13(4):449-54. PubMed ID: 24713592
[TBL] [Abstract][Full Text] [Related]
44. Once daily dosing of aminoglycosides.
Matthews Z; Cistulli K; Barnes D
Aust N Z J Med; 1994 Dec; 24(6):730; author reply 731. PubMed ID: 7717931
[No Abstract] [Full Text] [Related]
45. Variability of aminoglycosides pharmacokinesis in C.F. patients in relation with certain clinical parameters.
Douchain F; Lebas L; Houdas S; Chivet C; Bakhache P; Pautard JC
Acta Univ Carol Med (Praha); 1990; 36(1-4):37-9. PubMed ID: 2130714
[No Abstract] [Full Text] [Related]
46. Oral anti-pseudomonal antibiotics for cystic fibrosis.
Remmington T; Jahnke N; Harkensee C
Cochrane Database Syst Rev; 2007 Jul; (3):CD005405. PubMed ID: 17636796
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review.
Castagnola E; Cangemi G; Mesini A; Castellani C; Martelli A; Cattaneo D; Mattioli F
Int J Antimicrob Agents; 2021 Sep; 58(3):106381. PubMed ID: 34157401
[TBL] [Abstract][Full Text] [Related]
48. Inhaled antibiotics in cystic fibrosis.
Wall MA; Terry AB; Eisenberg J; McNamara M; Cohen R
Lancet; 1983 Jun; 1(8337):1325. PubMed ID: 6134106
[No Abstract] [Full Text] [Related]
49. Home intravenous antibiotic treatment in cystic fibrosis.
Strandvik B; Hjelte L; Widén B
Scand J Gastroenterol Suppl; 1988; 143():119-20. PubMed ID: 3164495
[TBL] [Abstract][Full Text] [Related]
50. [How should initial colonization by Pseudomonas aeruginosa be treated in patients with cystic fibrosis?].
David V
Rev Mal Respir; 2003 Apr; 20(2 Pt 2):S113-7. PubMed ID: 12910143
[No Abstract] [Full Text] [Related]
51. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
[TBL] [Abstract][Full Text] [Related]
52. Elusiveness of cystic-fibrosis treatment.
Littlewood JM; Govan JR
Lancet; 2001 Feb; 357(9256):633-4. PubMed ID: 11558508
[No Abstract] [Full Text] [Related]
53. Experience with ceftazidime in cystic fibrosis.
Dodge J; Zamiri I; Goodchild M; Ingram P
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():325-9. PubMed ID: 6352637
[TBL] [Abstract][Full Text] [Related]
54. Azlocillin and gentamicin in respiratory tract infections with Pseudomonas aeruginosa in patients with cystic fibrosis.
Malmborg AS; Alfredsson H; Kusoffsky E; Strandvik B
Scand J Infect Dis Suppl; 1981; 29():64-9. PubMed ID: 6947407
[TBL] [Abstract][Full Text] [Related]
55. Longitudinal analysis of FEV1 changes related to antibiotic therapy in children with cystic fibrosis.
Javadpour S; Jones A; Brownlee K
Ir Med J; 2007; 100(7):529-32. PubMed ID: 17886526
[TBL] [Abstract][Full Text] [Related]
56. Ceftazidime treatment of chronic Pseudomonas infection in patients with cystic fibrosis.
Fluge G; Digranes A; Michalsen H; Stiris T; Bergan T; Qvigstad EK
Eur J Respir Dis; 1987 Oct; 71(4):239-43. PubMed ID: 3319661
[TBL] [Abstract][Full Text] [Related]
57. [Cystic fibrosis: current therapy. Inhalation antibiotics].
Mordasini C
Schweiz Med Wochenschr Suppl; 2000; 122():43S-44S. PubMed ID: 12536472
[No Abstract] [Full Text] [Related]
58. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
Zabner R; Quinn JP
Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
[TBL] [Abstract][Full Text] [Related]
59. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
Permin H; Koch C; Høiby N; Christensen HO; Møller AF; Møller S
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():313-23. PubMed ID: 6352636
[TBL] [Abstract][Full Text] [Related]
60. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.
Kercsmar CM; Stern RC; Reed MD; Myers CM; Murdell D; Blumer JL
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():289-95. PubMed ID: 6352634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
